Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Meldonium - Grindeks

Drug Profile

Meldonium - Grindeks

Alternative Names: Kvaterin; MET-88; Mildronate; Quaterin

Latest Information Update: 04 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Latvian Institute of Organic Synthesis
  • Developer Grindeks; Taiho Pharmaceutical
  • Class Adjuvants; Antiarrhythmics; Cardiotonics; Ischaemic heart disorder therapies; Methylhydrazines; Propionates; Small molecules; Vasodilators
  • Mechanism of Action Gamma-butyrobetaine dioxygenase inhibitors; Partial fatty acid oxidation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Heart failure; Ischaemic heart disorders
  • No development reported Angina pectoris; Arrhythmias

Most Recent Events

  • 04 Jul 2016 Phase III development is ongoing in China
  • 30 May 2014 Phase-III clinical trials in Heart failure in China (IV)
  • 30 May 2014 Phase-III clinical trials in Heart failure in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top